ClinicalTrials.gg
Active, not recruitingNCT04333524PIMENTOUpdated Nov 12, 2026

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

An observational study in Marginal Zone Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG). Active, not recruiting at 25 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by International Extranodal Lymphoma Study Group (IELSG) · Observational

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
496
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) — 2 open to participants now, 6 under way, none of them phase 3. Lymphoma, B-Cell, Marginal Zone · International Extranodal Lymphoma Study Group (IELSG).

Started
2020
the only one that year
Observational
3 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG), this one is the only one that started in 2020, is one of 3 observational ones, and was the 9th registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

2 of the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG), or all of them as a file.
02

Study summary

The general aim of the present study is to assess the role of PET for the staging and for the assessment of response and outcome prediction in Marginal Zone Lymphoma (MZL). This study will be conducted as a multicenter retrospective analysis of MZL for whom PET scan are available as DICOM file for central review.

The study is designed as a retrospective collection of patients with MZL enrolled in the prospective IELSG36 and IELSG38 trials sponsored by IELSG and in the observational NF10 study sponsored by Federazione Italiana Linfomi (FIL), with the possibility to add additional cases from participating institutions.

The study will be conducted on performed scans. No additional scan or procedure will be required for study purposes.

The study will be divided into two sections with different aims:

Part A will be conducted to understand the role of PET for the staging of MZL. PET scans will be analyzed and compared with data retrieved from CT scan and from other staging procedures, also including bone marrow biopsy, ultrasound, and laboratory exams. This part of the study will describe ability of PET to identify pathologic lesions and to contribute to staging definition or to stage migration.

Part B will be conducted to validate standardized criteria for response assessment in MZL including FDG-PET among procedures and to define the prognostic role of metabolic response in MZL. For this purpose the primary endpoint for this part of the study is defined as the progression free survival. Secondary endpoint will be Overall survival, and response rate defined with conventional procedures and rate of histological transformation.

Read the detailed description

A significant proportion of patients considered for this study will be retrieved from previous observational prospective clinical studies. Data on clinical presentation, treatment and follow-up will be obtained from the existing dataset of the previous protocols. For the additional cases identified from clinical practice data will be collected from patient chart. A unique study CRF will be prepared to collect all the required details.

Patients with histologically confirmed marginal zone lymphomas according to the current WHO classification are registered in the study. Moreover, patients characteristics (PS, systemic symptoms), Ann Arbor stage, laboratory parameters, serology for hepatitis C, B and human immunodeficiency virus, bone marrow aspirate and biopsy data, data on treatment start and end, chemotherapy details, final response defined according to Cheson 2014 and Matutes criteria, date of last follow-up ,occurrence of any event (relapse, progression, death) with date will be collected.

PET response will be initially coded according to local interpretation of scan report. All FDG-PET, will be then centralized to perform a blinded independent review of staging and response. Images will be centralized and examined by a panel of 3 nuclear medicine physicians that will independently review the scans. Each case will be evaluated by two reviewers. In case of discordant results a third reviewer will adjudicate the case.

Each patient enrolled in the study will be anonymized by assigning a unique identification numerical code upon registration in the study. The unique identification code will be used to record health-related data.

Anonymized PET data will be uploaded into the DICOM system by the responsible person of the site.

Anonymized health-related data will be collected in the e-CRF. At each site, the responsible of the research or a delegated person will complete the e-CRF.

Only the Study Chair and the Sponsor will have access rights for the health-related data and will be responsible for protection of the data.

03

Conditions studied

  • Marginal Zone Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with MZL enrolled in the prospective IELSG36 and IELSG38 trials and on the observational NF10, with the possibility to add additional cases from participating institutions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. One of the following subtypes of Histology confirmed Indolent non-follicular B-cell lymphoma:

    • Splenic MZL (bone marrow histology and/or splenic tissue);
    • Extranodal MZL or MALT (tissue );
    • Nodal MZL (lymph node biopsy).
  2. Age over 18.
  3. Availability of details on clinical presentation, treatment details and results, and on follow-up.
  4. Execution of PET at diagnosis or/and at end of treatment or/and at relapse.
  5. Execution of CT scan with iodine contrast medium at diagnosis and at assessment of response.
  6. Patients with confirmed marginal zone lymphomas according to the current WHO classification are registered in the study. Diagnosis based on tru-cut core-needle biopsies are permitted in the study.
  7. Written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with a diagnosis of Non Hodgkin Lymphoma other than MZL.
  2. Scans images not available for whatever reason.
  3. Cases diagnosed on fine needle aspiration cytology only.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
496 participants (actual)
Patient registry
No

Groups and cohorts

  • Group A

    Staging

  • Group B

    Criteria for response assessment

06

What researchers measure

Primary outcomes

  1. Correlation between CT and PET

    To correlate CT and PET results for stage definition

    Time frame: At baseline

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: From date of enrollment until the date of first documented progression, or last follow up, or date of death from any cause, whichever came first, assessed up to a maximum of 10 years

  2. Duration of Response (DoR)

    DoR is evaluated only for responding patients

    Time frame: From date of first response to the date of relapse, or last follow up, or date of death from any cause, whichever came first, assessed up to a maximum of 10 years

07

Study locations

25 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2020 (actual). Primary completion is estimated for Feb 2027, 74 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Feb 2027 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2020
First posted
Apr 3, 2020
StartActual
Dec 1, 2020
Primary completionEst.
Feb 15, 2027was Oct 2026
CompletionEst.
Feb 15, 2027was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 15, 2026→Feb 15, 2027
Nov 12, 2026
Study completion
Oct 15, 2026→Feb 15, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 15, 2026→Feb 15, 2027
    Study completion Oct 15, 2026→Feb 15, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04333524
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Dec 1, 2020
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Stefano Luminari, MD
study chair · AUSL IRCCS - Reggio Emilia (Italy)
Catherine Thieblemont, MD
study chair · Saint-Louis Hospital, Paris, France
Emanuele Zucca, MD
study chair · Oncology Institute of Southern Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion